Key Highlights
- Baxter sells Kidney Care segment to Carlyle for $3.8 billion, forming Vantive.
- Transaction supports Baxter’s strategic realignment and debt reduction.
- Vantive to focus on advancing kidney and vital organ therapies under Carlyle’s stewardship.
- Carlyle partners with Atmas Health to lead Vantive with experienced industry executives.
Source: Direct
Notable Quotes
- “Today’s announcement represents another critical step forward in the strategic transformation process we announced in early 2023.” — José E. Almeida, Chair, President & CEO at Baxter
- “Vantive will be well-positioned to deepen our commitment to elevating dialysis through digital solutions and advanced services.” — Chris Toth, CEO at Vantive
- “We are delighted to partner with the Vantive team to pursue their strategic vision through the separation from Baxter and transformation into a standalone global business.” — Robert Schmidt, Global Co-Head of Healthcare at Carlyle
SoHC's Take
This transaction is a significant move for both Baxter and Carlyle, reflecting Baxter’s strategic shift toward streamlining operations and focusing on high-growth areas. The creation of Vantive under Carlyle’s ownership, with the experienced leadership of Chris Toth and the Atmas Health team, sets the stage for innovation in kidney care and vital organ therapies. Baxter’s focus on deleveraging and enhancing its core business, combined with Vantive’s potential under Carlyle, is poised to create long-term value for stakeholders across both companies. The successful completion of this deal will likely reshape the competitive landscape in the global medtech sector.
